Opinion|Videos|May 7, 2024
Evaluating the Impact of Metastatic Breast Cancer on Patients
An expert panel discusses the clinical and economic impact of metastatic breast cancer (mBC) on patients, the prognosis for those with mBC, the three FDA-approved CDK4/6 inhibitors for HR+/HER2- mBC, and the importance of overall survival as a clinical trial endpoint and its relevance to clinical practice.
Advertisement
Episodes in this series
Advertisement
Related to this article
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk-funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, though the findings cannot show causation.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A retrospective study from Japan found that oncology pharmacist assessment before medical examination was associated with higher rates of complete adverse event resolution in outpatient chemotherapy.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
In SCOUT-HCM, mavacamten reduced the Valsalva LVOT gradient by 48 mm Hg versus placebo in adolescents. REMS, echo monitoring, and CYP interactions still apply in the new population.
September’s pain management coverage examined postoperative nonopioid options, lessons from sickle cell pain research, and pharmacists’ experiences with controlled-substance prescribing.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
3
Semaglutide 2 mg Tied to Lower MACE Risk Than Tirzepatide Switch
4
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
5